Infinity Pharmaceuticals, Inc. (IPI) is a drug discovery and development company. The Company's lead product is a potent, oral inhibitor of Class I PI3K-delta and PI3K-gamma, which the Company is investigating in both hematologic malignancies and inflammatory diseases.Its retaspimycin hydrochloride (HCl), is a potent and selective inhibitor of heat shock protein 90 (Hsp90). The phosphoinositide-3-kinases (PI3Ks) are key cellular signaling proteins that act as a central node for relaying signals from cell surface receptors to downstream biochemical events. The Company's lead development candidate in this program is IPI-145 a potent, oral inhibitor of Class I PI3K-delta,gamma for which clinical trials are conducted form both hematologic malignancies and inflammatory diseases. Hematologic malignancies are cancers of the blood or bone marrow and include leukemia and lymphoma, such as chronic lymphocytic leukemia (CLL), Hodgkin lymphoma, and non-Hodgkin lymphoma (NHL).
|Headquarters||780 Memorial Drive|
CAMBRIDGE, MA, United States 02139
|Chairman of the Board, President, Chief Executive Officer||Adelene Perkins|
|Chief Financial Officer, Executive Vice President, Chief Business Officer||Lawrence Bloch|
|President - Research & Development||Julian Adams|
|Chief Scientific Officer||Vito Palombella|
|Vice President - Marketing||Winselow Tucker|
With TD Waterhouse, you have access to the industry's leading selection of independent research reports from providers such as TDSI, TD Securities, S&P, INK and Argus.
|Shares Out.||49.2M||Book Value||$6.53|
|Annual Dividend Rate||$0.00||Price/Sales (TTM)||38.6|
|Ex-Div Date||1/1/01||P/Cash Flow (TTM)||--|
|Pay Date||1/1/01||Operating Margin||-320.87%|
*GAAP = prior to non-GAAP analyst adjusted earnings.